Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma

Lenvatinib was recently approved as a novel first-line molecular targeted agent (MTA) for treating hepatocellular carcinoma (HCC). The importance of relative dose intensity (RDI) has been shown in the treatment of various types of cancers. However, RDI may not accurately reflect the treatment intens...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Eso, Yuji, Nakano, Shigeharu, Mishima, Masako, Arasawa, Soichi, Iguchi, Eriko, Nakamura, Fumiyasu, Takeda, Haruhiko, Takai, Atsushi, Takahashi, Ken, Taura, Kojiro, Seno, Hiroshi
Format: Artigo
Language:Inglês
Published: MDPI 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016578/
https://ncbi.nlm.nih.gov/pubmed/31877859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12010049
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items